Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

Jim Young, Juliane Schäfer, Christoph A. Fux, Hansjakob Furrer, Enos Bernasconi, Pietro Vernazza, Alexandra Calmy, Matthias Cavassini, Rainer Weber, Manuel Battegay,

AIDS · 2012 · 88 citations · 30 references

Abstract

Tenofovir with either boosted protease inhibitor leads to a greater initial decline in eGFR than tenofovir with efavirenz; this decline may be worse with ATV/r than with LPV/r.

References

30